Precigen, Inc. (PGEN)
NASDAQ: PGEN · IEX Real-Time Price · USD
1.415
+0.015 (1.07%)
May 3, 2024, 10:34 AM EDT - Market open
Precigen Revenue
In the year 2023, Precigen had annual revenue of $6.23M, a decrease of -76.87%. Revenue in the quarter ending December 31, 2023 was $1.23M, a -30.35% decrease year-over-year.
Revenue (ttm)
$6.23M
Revenue Growth
-76.87%
P/S Ratio
56.77
Revenue / Employee
$30,817
Employees
202
Market Cap
358.44M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
Dec 31, 2021 | 14.27M | -17.73M | -55.40% |
Dec 31, 2020 | 31.99M | -58.73M | -64.74% |
Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
Dec 31, 2014 | 71.93M | 48.17M | 202.74% |
Dec 31, 2013 | 23.76M | 9.99M | 72.50% |
Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
Dec 31, 2011 | 8.01M | - | - |
Dec 31, 2010 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.76B |
Zynex | 184.32M |
Surmodics | 138.20M |
Heron Therapeutics | 127.04M |
CVRx, Inc. | 39.30M |
Immutep | 4.58M |
Q32 Bio | 1.16M |
PGEN News
- 9 days ago - Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients with Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting - PRNewsWire
- 9 days ago - Actym Therapeutics Appoints Thomas Smart as CEO - PRNewsWire
- 5 weeks ago - Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th - PRNewsWire
- 6 weeks ago - Precigen Reports Full Year 2023 Financial Results and Business Updates - PRNewsWire
- 7 weeks ago - Precigen to Participate in a Fireside Chat Hosted by Cantor Fitzgerald to Discuss PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis - PRNewsWire
- 2 months ago - Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th - PRNewsWire
- 3 months ago - Precigen to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference - PRNewsWire
- 3 months ago - Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission - PRNewsWire